According to a new report, published by KBV research, The Global Botulinum Toxin Market size is expected to reach $10.5 billion by 2028, rising at a market growth of 10.8% CAGR during the forecast period.
The Type B segment has shown the growth rate of 19.7% during (2022 - 2028). The rapid surge in the growth of the segment is owing to the rising demand for botulinum toxin in the cosmetic industry. Every year, a significant number of cosmetic surgeries are being performed across the world. Botulinum toxin can substantially aid in the treatment of wrinkles on the face of patients.
The Therapeutic segment acquired maximum revenue share in the Global Botulinum Toxin Market by Application in 2021 thereby, achieving a market value of $5.9 billion by 2028. The most potent biological neurotoxic molecule identified is known as botulinum toxin, and it shows significant promise for the treatment of numerous illnesses.
The Hospitals segment is showcasing a CAGR of 10.3 % during (2022 - 2028). The expansion of this segment is being aided by an increase in hospitals offering cutting-edge medical treatment and amenities in both developed as well as emerging nations, and by growing public awareness of aesthetic operations.
The North America market dominated the Global Botulinum Toxin Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $3.8 billion by 2028.The Europe market is exhibiting a CAGR of 10.6% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 11.4% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/botulinum-toxin-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Evolus, Inc. (Alphaeon Corporation), Merz Pharma GmbH & Co. KGaA, AbbVie, Inc., Ipsen Pharma, Galderma S.A., USWM, LLC, and Metabiologics, Inc. (Object Pharma).
By Product
By Application
By End User
By Geography
Companies Profiled
Unique Offerings 
